> Skip repeated content
photo of Jessica K. Gordon, MD

Jessica K. Gordon, MD

Rheumatology
phone icon

About Dr. Gordon

loading...
 

Dr. Jessica Gordon is an Associate Attending Physician in the Division of Rheumatology at Hospital for Special Surgery and an Associate Professor of Clinical Medicine at Weill Cornell Medicine. She specializes in the treatment of patients with systemic sclerosis (scleroderma), and her research focus is developing improved therapies for patients with this condition. She also specializes in the care patients with Raynaud phenomenon, mixed connective tissue disease, interstitial lung disease associated with connective tissue disease, Sjogren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis, and other conditions. She is the HSS Scleroderma clinic chief. She has been recognized for several years as a "Top Doctor" by Castle/Connolly and New York magazine.

Dr. Gordon completed her undergraduate studies at Brown University in 1993. She received her MD degree from State University of New York at Stony Brook where she graduated Alpha Omega Alpha. She completed her internal medicine residency and chief residency at Georgetown University Hospital in Washington, DC. She then went on to complete her fellowship in Rheumatology at Hospital for Special Surgery. Following this she joined the faculty at HSS in 2010 where she continues to practice Rheumatology.

Dr. Gordon conducts clinical and translational research in systemic sclerosis. She is an investigator in multiple clinical trials and observational studies with this focus. She has been the recipient of numerous grants and awards including the Kellen Family Clinical Scientist Development Award, the Scleroderma Foundation New Investigator Grant, the Charles L. Christian Award for Excellence in Musculoskeletal Research, and the American College of Rheumatology Distinguished Fellow Award.

Departments

Specialized Centers

Scleroderma, Vasculitis & Myositis Center of Excellence

Special Expertise

Associated interstitial lung disease
Connective tissue disease
Eosinophilic fasciitis
Inflammatory arthritis
Inflammatory myopathy
Localized scleroderma/Morphea
Mixed connective tissue disease
Raynaud phenomenon
Rheumatoid arthritis
Sjogren’s syndrome
Systemic lupus erythematosus
Systemic sclerosis/scleroderma

Procedures

Intra-articular and intra-bursal aspirations and injections

Patient Stories

Videos

Patient ratings for Dr. Gordon

loading...

Learn more about our patient ratings.

Insurance

If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.

Credentials

Appointments

Associate Attending Physician, Hospital for Special Surgery
Associate Professor of Medicine, Weill Cornell Medical College

Affiliations

Member, American College of Rheumatology
Member, American Medical Association
Scleroderma Foundation Medical Advisory Board

Certification

Rheumatology, 2008
Internal Medicine, 2005

Awards

Castle Connolly Top Doctor, 5 years
Castle Connolly Top Doctors in New York Metro Area, 2017-2022
Castle Connolly Regional Top Doctor, 2017-2020
New York Magazine Top Doctors, 2017-2022
Exceptional Women In Medicine: 2019-2020
Charles L. Christian Award for Excellence in Musculoskeletal Research, 2010
Department of Medicine Fellow Award - Finalist, 2010
American College of Rheumatology Distinguished Fellow Award, 2009
Certificate of Appreciation – Scleroderma Foundation – Tristate Chapter, 2009
Donald Knowlan Award, Georgetown University Hospital, Dept. of Internal Medicine, 2005
Janet Glasgow Memorial Achievement Citation, American Medical Women’s Society, 2002
Alpha Omega Alpha Honor Society, 2001

Education

MD, State University of New York at Stony Brook, Stony Brook, NY 2002
MS, Clinical Investigation, Cornell University, NY 2010

Internship

Internal Medicine, Georgetown University Hospital, Washington, DC

Residency

Internal Medicine, Georgetown University Hospital, Washington, DC

Fellowship

Rheumatology, Hospital for Special Surgery

State Licensure

Languages

English, Spoken by Office Staff: Spanish

Publications by Dr. Gordon

Patient Education

Professional Education

Selected Journal Articles

Selected Books/Chapters

  • Gordon JK, Goldenberg D, Erkan D, Lockshin M.  (2009)  Difficult Situations in the Antiphospholipid Syndrome.  Handbook of Systemic Autoimmune Diseases, Volume 10. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. (Eds. Ricard Cervera, Joan Carles Reverter and Munther Khamashta), 215 – 233.

Selected Presentations

  • Gordon JK, Spiera RF, Mersten JN, Wildman HF, Taime Z, Hackett, NR, Vukelic S, Kirou K, Crow MK. Does Treatment with Imatinib Modify Gene Expression in the Skin and Peripheral Blood Mononuclear Cells of Patient with Systemic Sclerosis? American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
  • Gordon JK, Gomberg-Maitland M, Segal B, Domsic R, Shah A, Hummers L, Steen V, Horn E and the PHAROS Investigators. Difficulty Using World Health Organization Criteria to Categorize Pulmonary Hypertension in Patients with Systemic Sclerosis. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
  • Spiera RF, Gordon JK, Mersten J, Magro CM, Mehta M, Wildman HF, Kloiber SA, Kirou KA, Lyman, S, Crow MK. Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
  • Gordon JK,  Vukelic S, Magro CM, Mersten J, Wildman HF, Crow MK, Kirou KA and Spiera RF.  Histologic and Molecular Basis of Improved Skin Scores in Scleroderma Patients Treated with Imatinib Mesylate (Gleevec.) Abstract 1727.  American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
  • Gordon JK, Mersten J, Lyman S, Kloiber SA, Wildman HF, Crow MK, Kirou KA and  Spiera RF.  Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial.  Presentation 606. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
  • Taimeh Z, Gordon JK, MacDermott EJ, Barillas L, Mersten J, Duculan R, Spiera RF, Crow MK, Kirou KA. Elevated sVEGFR-1 Is a Candidate Biomarker for Pulmonary Dysfunction in Patients with Systemic Sclerosis.  Abstract 466. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
  • Spiera RF Gordon JK Mehta M Kirou KA Lyman S Kloiber SA Crow MK. (2008).  Phase IIa Trial of Imatinib Mesylate (Gleevec) in the Treatment of Diffuse Systemic Sclerosis - An Interim Analysis. Arthritis and Rheumatism 58(10): S1222.
  • Gordon JK, Magid S, Berman E. (2008). Elevations in Creatine Kinase Occur Frequently in Patients Treated with Imatinib Mesylate (Gleevec.) Abstract F15/469, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
  • Gordon JK, Taimeh Z, Markopoulou A, Mersten J, Crow MK, Kirou KA.  (2008). High Levels of Activated ERK in Monocytes of Patients with Scleroderma. Abstract F2/456, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
  • Gordon JK, Steen V. (2005).  African American Scleroderma Patients Have Altered Body Image. Arthritis and Rheumatism 52(9): S585.

Research

Research Interests

Scleroderma

Clinical Trials / Research Studies

Patient Registries

Industry Relationships

Industry Relationships

HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.

Below are the healthcare industry relationships reported by Dr. Gordon as of February 16, 2024.

  • Cumberland Pharmaceuticals - Anticipate Receiving Research Support
  • Merck - Anticipate Receiving Research Support

HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.

Patients should feel free to ask their HSS physicians questions about these relationships.

Dr. Gordon in the News